ClinicalTrials.gg
RecruitingNCT07858656Updated Nov 4, 2026

Vagus Nerve Stimulation on Improving Sleep in Inpatient Rehab for Post-Acute Stroke

An interventional study of transauricular Vagal Nerve Stimulation and Sham Comparator in Stroke, Ischemic Cerebrovascular Accident and Ischemic Stroke, sponsored by Casa Colina Hospital and Centers for Healthcare. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Casa Colina Hospital and Centers for Healthcare · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Planned enrollment
208th of 364
52 · median 65
Started
2026
with 35 others
No phase
183 of 480
51 open now
Primary completion
2027-10
later than 78 of 144 live
Registered
478th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 208th largest by planned enrollment of the 364 interventional ones that give a count, is one of 36 that started in 2026, is one of 183 with no phase, reaches primary completion later than 78 of the 144 other live ones, and was the 478th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

114 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a device which provides vagal nerve stimulation, applied to the tragus of the ear via an ear clip, can improve sleep in individuals recovering from stroke while they are treated in a rehabilitation hospital. The main questions this study aims to answer are:

  1. Does using this device improve insomnia?
  2. Does this device have any impact on the person's stroke severity, mobility, self-care, or ability to think? Researchers will compare this treatment to a sham (a look-alike device that will not deliver the stimulation).

Participants will:

  • Complete questionnaires about insomnia and their ability to think
  • Use the device for 30 minutes every evening for at least 10 nights during their inpatient stay
  • Complete a log tracking their use of the device and any concerns
Read the detailed description

For this randomized control trial, all patients admitted to Casa Colina's acute rehabilitation unit with a diagnosis of stroke will be screened against inclusion and exclusion criteria. Participants will be assessed using a cognition screen via the Mini Mental Exam and the Insomnia Severity Index (ISI), a validated tool for measuring and grading the presence of insomnia. The initial assessments will be completed within the first 3-5 days from admission to the acute rehabilitation unit. Participants will be randomized into the intervention group or sham treatment group. All participants will receive a handout on sleep hygiene. All participants will be instructed around the use of the non-invasive taVNS Parasym device (by Parasym Ltd., London) and the training log which will include reporting of any side effects and any other personal bedtime routines to assist with sleep. In line with previous studies investigating the impact of taVNS on other post-stroke symptoms, the intervention group will be instructed to utilize the Parasym device for 30min daily between 7-9pm for at least 10 days following. Stimulation parameters will be set at 200µs pulse width (with proprietary waveform) and 20Hz. The intensity will be set to level 21 and increased up to 32 as tolerated, but reduced sequentially to intensity level 12 if unable to tolerate due to discomfort. They will include amplitudes 1.0-1.7mA for therapeutic thresholds previously studied in stroke research (Li 2022) and allow for uniformity of application of the device between treatment and sham groups. The sham treatment group will be instructed in using the Parasym device the same way, however, their issued devices will include a sham earpiece that will prevent the transmission of taVNS. Reassessment of the ISI will be completed at 12-15 days, or earlier if the patient discharges prior to this timeline. A short 2-week taVNS program has been reported to have some effect on insomnia (Liu 2025) in a non-stroke population and this timeline has also been chosen as it coincides with the current typical length of stay for individuals post stroke in the acute rehabilitation unit.

All participants of the study will continue to receive the usual care for their individual rehabilitation program including therapy and medication interventions. Additional data will be collected beyond the screening tests including demographic information, stroke location, time since stroke, history of prior stroke, history of diabetes, NIH stroke scale on admission, record of medications that may impact sleep, consult to neurology service, use of respiratory devices on admission or during their rehab course (supplemental O2, CPAP, BiPAP), and GG and C scores of the IRF-PAI for mobility, self-care, and cognition.

03

Conditions studied

  • Stroke
  • Ischemic Cerebrovascular Accident
  • Ischemic Stroke
  • Vagal Nerve Stimulation

Browse trials for

Keywords

  • Vagal Nerve Stimulation
  • Post Acute Care
  • Stroke
  • Cerebrovascular Accident
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 52 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Casa Colina Hospital and Centers for Healthcare is the lead sponsor of 16 studies on the registry; 11 are open to participants now.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Admitted to Casa Colina's acute rehabilitation service
  2. Diagnosis of ischemic stroke
  3. Age 18 years or older
  4. English or Spanish speaking
  5. Sufficient cognition to follow program instructions tested Mini Mental Exam (score >17/30)
  6. Confirmed sleep abnormalities based on the Insomnia Severity Index (ISI) meeting criteria for subthreshold or clinical insomnia (score >7/28)

Exclusion criteria

Exclusion Criteria:

  1. Hemorrhagic stroke or hemorrhagic conversion of ischemic stroke
  2. Other confirmed neurological diagnoses
  3. Previous surgical intervention on the vagus nerve
  4. Any open wound or cancerous lesions at the ear within 1 inch of the ear tragus
  5. to the device, including patients with severe bradycardia, patients with a permanent implanted metallic or electronic device or jewelry at close proximity (2cm) to the ear tragus, patients with a recent (within 1 year) history of trigeminal neuralgia, pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    transauricular Vagal Nerve Stimulation (taVNS)

    Participants will be assessed for cognition via the Mini Mental Exam and the Insomnia Severity Index (ISI). The initial assessments will be completed within the first 3-5 days from admission to the acute rehabilitation unit. Participants will receive a handout on sleep hygiene. Participants will be instructed around the use of the non-invasive taVNS Parasym device (by Parasym Ltd., London) and the training log which will include reporting of any side effects and any other personal bedtime routines to assist with sleep. The participant will be instructed to utilize the Parasym device for 30min daily between 7-9pm for at least 10 days following. Reassessment of the ISI will be completed at 12-15 days, or earlier if the patient discharges prior to this timeline. These participants will continue to receive the usual care for their individual rehabilitation program including therapy and medication interventions.

    Device: transauricular Vagal Nerve Stimulation

  • Sham comparator
    Sham transauricular Vagal Nerve Stimulation (Sham taVNS)

    Participants will be assessed for cognition via the Mini Mental Exam and the Insomnia Severity Index (ISI). The initial assessments will be completed within the first 3-5 days from admission to the acute rehabilitation unit. Participants will receive a handout on sleep hygiene. Participants will be instructed around the use of the non-invasive taVNS Parasym device (by Parasym Ltd., London) and the training log which will include reporting of any side effects and any other personal bedtime routines to assist with sleep. The participant will be instructed to utilize the Parasym device for 30min daily between 7-9pm for at least 10 days following. For this group, their issued devices will include a sham earpiece that will prevent transmission of taVNS. The ISI will be re-assessed at 12-15 days, or earlier if the patient discharges prior to this timeline. Participants will continue to receive the usual care for their individual rehabilitation program, including therapy and medications.

    Device: Sham Comparator

Interventions

  • Devicetransauricular Vagal Nerve Stimulation

    All participants will be instructed around the use of the non-invasive taVNS Parasym device (by Parasym Ltd., London). Participants will be instructed to utilize the Parasym device for 30min daily between 7-9pm for at least 10 days following. Stimulation parameters will be set at 200µs pulse width (with proprietary waveform) and 20Hz. The intensity will be set to level 21 and increased up to 32 as tolerated, but reduced sequentially to intensity level 12 if unable to tolerate due to discomfort. They will include amplitudes 1.0-1.7mA for therapeutic thresholds.

  • DeviceSham Comparator

    All participants will be instructed around the use of the non-invasive taVNS Parasym device (by Parasym Ltd., London). Participants will be instructed to utilize the Parasym device for 30min daily between 7-9pm for at least 10 days following. Stimulation parameters will be set to the same parameters as for the experimental group, however his device will include a sham earpiece that will prevent the transmission of taVNS.

07

What researchers measure

Primary outcomes

  1. Insomnia Severity Index

    A brief screening tool for insomnia including seven items assessing the nature and symptoms of their sleep issues. Questions relate to the responder's sleep, symptom severity and satisfaction with their sleep, as well as the effect of their insomnia on daily function, social impact, and overall distress related to their sleep. Each question is answered on a 5-point Likert scale. Total scores range from 0-28, with a higher score indicating worse insomnia severity.

    Time frame: Initial assessment on Day 3-5 of their inpatient stay. Reassessment at 12-15 days, or earlier if the patient discharges prior to this timeline.

Secondary outcomes

  1. Inpatient Rehabilitation Facility Patient Assessment Instrument (IRF-PAI) Admission and Discharge Scores - GG and C sections

    Standardized assessments by the healthcare team regarding level of assistance required by the participant for mobility, self-care, and cognition. The GG section assesses self-care (7 items) and mobility (17 items) on a scale from 1-6, with a higher number indicating greater independence. If a participant is unwilling or unsafe to perform an activity, or if the activity is not applicable or there is an environmental limitation, special codes can be applied. The C section of the IRF-PAI assesses cognition via the Brief Interview for Mental Status comprising repetition of 3 words, temporal orientation, and recall. Participants are scored in this section from 1-15 with a higher score indicating better cognition. The presence of any acute-onset mental status change is considered here.

    Time frame: Assessed within 48 hours of admission, re-assessed at discharge (with a typical length of stay of 12 to 15 days).

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Zhao B, Li L, Jiao Y, Luo M, Xu K, Hong Y, Cao JD, Zhang Y, Fang JL, Rong PJ. Transcutaneous auricular vagus nerve stimulation in treating post-stroke insomnia monitored by resting-state fMRI: The first case report. Brain Stimul. 2019 May-Jun;12(3):824-826. doi: 10.1016/j.brs.2019.02.016. Epub 2019 Feb 21. No abstract available. PubMed 30871845 ↗
  • Sun J, Li X, Zhou Y, Liu H, Ma C, Hao C, Liu S, Zhao J, Zhang X, Xiao X. Clinical advances in transcutaneous auricular vagus nerve stimulation for post-stroke disorders: state of the art and future perspectives. Front Neurol. 2025 Oct 31;16:1676727. doi: 10.3389/fneur.2025.1676727. eCollection 2025. PubMed 41245869 ↗
  • Niu S, Wu Q, Ding S, Wu L, Wang L, Shi Y. Comparison of three measures for insomnia in ischemic stroke patients: Pittsburgh sleep quality index, insomnia severity index, and Athens insomnia scale. Front Neurol. 2023 Aug 30;14:1118322. doi: 10.3389/fneur.2023.1118322. eCollection 2023. PubMed 37712082 ↗
  • Meng R, Huang M, Miller CB, Fong DYT, Gregory AM, Pakpour AH, Dzierzewski JM, Henry AL, Voinescu BI, Yang N, Ma H, Luo Y, Lau EYY, Spruyt K, Espie CA. Global perspectives on the Sleep Condition Indicator for DSM-5 insomnia disorder: a COSMIN and STARD systematic review of psychometric and diagnostic performance. BMC Med. 2025 Oct 8;23(1):542. doi: 10.1186/s12916-025-04285-7. PubMed 41063190 ↗
  • Liu W, Li G. The Latest Advances in Non-Invasive Neurostimulation for Insomnia: A Review. Nat Sci Sleep. 2025 May 15;17:947-957. doi: 10.2147/NSS.S501619. eCollection 2025. PubMed 40395454 ↗
  • Jackowska M, Koenig J, Vasendova V, Jandackova VK. A two-week course of transcutaneous vagal nerve stimulation improves global sleep: Findings from a randomised trial in community-dwelling adults. Auton Neurosci. 2022 Jul;240:102972. doi: 10.1016/j.autneu.2022.102972. Epub 2022 Mar 16. PubMed 35364413 ↗
  • de Oliveira HM, Gallo Ruelas M, Viana Diaz CA, Oliveira de Paula G, Fruett da Costa PR, Pilitsis JG. Transcutaneous Auricular Vagus Nerve Stimulation in Insomnia: A Systematic Review and Meta-Analysis. Neuromodulation. 2025 Dec;28(8):1332-1340. doi: 10.1016/j.neurom.2025.04.001. Epub 2025 May 5. PubMed 40323248 ↗
  • Gao L, Fan Y, Zhang N, Chen L. Transcutaneous Auricular Vagus Nerve Stimulation Paired With Exercise Training for Upper Limb Motor Function and Activities of Daily Living After Stroke: A Systematic Review and Meta-analysis. Arch Phys Med Rehabil. 2026 Mar 20:S0003-9993(26)00617-9. doi: 10.1016/j.apmr.2026.03.008. Online ahead of print. PubMed 41865861 ↗
  • Li L, Wang D, Pan H, Huang L, Sun X, He C, Wei Q. Non-invasive Vagus Nerve Stimulation in Cerebral Stroke: Current Status and Future Perspectives. Front Neurosci. 2022 Feb 16;16:820665. doi: 10.3389/fnins.2022.820665. eCollection 2022. PubMed 35250458 ↗
  • Fernandez-Mendoza J, Rodriguez-Munoz A, Vela-Bueno A, Olavarrieta-Bernardino S, Calhoun SL, Bixler EO, Vgontzas AN. The Spanish version of the Insomnia Severity Index: a confirmatory factor analysis. Sleep Med. 2012 Feb;13(2):207-10. doi: 10.1016/j.sleep.2011.06.019. Epub 2011 Dec 14. PubMed 22172961 ↗
  • Du L, He X, Xiong X, Zhang X, Jian Z, Yang Z. Vagus nerve stimulation in cerebral stroke: biological mechanisms, therapeutic modalities, clinical applications, and future directions. Neural Regen Res. 2024 Aug 1;19(8):1707-1717. doi: 10.4103/1673-5374.389365. Epub 2023 Nov 8. PubMed 38103236 ↗
  • Cai H, Wang XP, Yang GY. Sleep Disorders in Stroke: An Update on Management. Aging Dis. 2021 Apr 1;12(2):570-585. doi: 10.14336/AD.2020.0707. eCollection 2021 Apr. PubMed 33815883 ↗
  • Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307. doi: 10.1016/s1389-9457(00)00065-4. PubMed 11438246 ↗

Individual participant data

Plan to share: No

10

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 12 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Sep 2026 → Oct 2026, primary completion Sep 2027 → Oct 2027 and completion Nov 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartActual
Oct 16, 2026was Sep 2026
Primary completionEst.
Oct 16, 2027was Sep 2027
CompletionEst.
Dec 16, 2027was Nov 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
Casa Colina Hospital and Centers for Healthcare is now Recruiting
Nov 4, 2026
Start date
Sep 4, 2026→Oct 16, 2026
Oct 8, 2026
Primary completion
Sep 4, 2027→Oct 16, 2027
Oct 8, 2026
Study completion
Nov 4, 2027→Dec 16, 2027
Oct 8, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionInsomnia Severity Index: how it is measured was reworded
Oct 8, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionInpatient Rehabilitation Facility Patient Assessment Instrument (IRF-PAI) Admission and Discharge Scores - GG and C sections: how it is measured was reworded
Oct 8, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 3 updates
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    Casa Colina Hospital and Centers for Healthcare is now Recruiting
    + 2 other changes: verification date and date precision
  2. Oct 8, 2026
    Start date Sep 4, 2026→Oct 16, 2026
    Primary completion Sep 4, 2027→Oct 16, 2027
    Study completion Nov 4, 2027→Dec 16, 2027
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionInsomnia Severity Index: how it is measured was reworded
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionInpatient Rehabilitation Facility Patient Assessment Instrument (IRF-PAI) Admission and Discharge Scores - GG and C sections: how it is measured was reworded
    + 1 other change: verification date
  3. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07858656
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 16, 2026
Primary completion
Oct 16, 2027 (estimated)
Completion
Dec 16, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Marie Yeseta, PT, DPT, NCS
Contact
myeseta@casacolina.org
9095967733 ext. 3111
Hannah Cone, PT, DPT, NCS
Contact
HCone@casacolina.org
9095967733 ext. 3111
Emily Rosario, PhD
study director · Casa Colina Hospital and Centers for Healthcare

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion